Payment overview · 2025
General Payments
$293.26
15 reported records · 8 companies
Healthcare provider profile · identity verified
Mohamed S Kholoki, MD
Allopathic & Osteopathic Physicians|General Practice · LAGRANGE PARK, IL · NPI 1275679755
Verified facts
What the public records show
CMS Open Payments records show Mohamed S Kholoki, MD received $293.26 in general payments during 2025 across 15 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 27.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 463 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 463 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $81.12 | 27.7% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $74.04 | 25.2% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.31 | 11.0% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $27.40 | 9.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.30 | 8.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.11 | 6.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.93 | 6.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.05 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $293.26 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $81.12 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $50.09 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $32.31 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $32.31 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $27.40 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $23.30 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.98 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.98 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.98 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $20.11 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 463 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
463 | 67 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
463 | 67 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 612 | 164 |
| Metoprolol Succinate | Metoprolol Succinate | 514 | 141 |
| Eliquis | Apixaban | 463 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 446 | 111 |
| Losartan Potassium | Losartan Potassium | 417 | 120 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 407 | 134 |
| Metoprolol Tartrate | Metoprolol Tartrate | 406 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 365 | 93 |
| Tamsulosin Hcl | Tamsulosin Hcl | 355 | 85 |
| Gabapentin | Gabapentin | 316 | 66 |
| Famotidine | Famotidine | 278 | 46 |
| Hydralazine Hcl | Hydralazine Hcl | 273 | 67 |
| Furosemide | Furosemide | 263 | 70 |
| Omeprazole | Omeprazole | 249 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 242 | 73 |
| Allopurinol | Allopurinol | 222 | 71 |
| Prednisone | Prednisone | 217 | 111 |
| Montelukast Sodium | Montelukast Sodium | 216 | 68 |
| Simvastatin | Simvastatin | 208 | 53 |
| Enoxaparin Sodium | Enoxaparin Sodium | 207 | suppressed |
| Torsemide | Torsemide | 197 | 47 |
| Metformin Hcl | Metformin Hcl | 178 | 55 |
| Potassium Chloride | Potassium Chloride | 173 | 56 |
| Meloxicam | Meloxicam | 170 | 49 |
| Mirtazapine | Mirtazapine | 166 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 149 | 37 |
| Alprazolam | Alprazolam | 145 | 52 |
| Carvedilol | Carvedilol | 144 | 32 |
| Memantine Hcl | Memantine Hcl | 143 | 16 |
| Donepezil Hcl | Donepezil Hcl | 129 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 129 | 18 |
| Lisinopril | Lisinopril | 128 | 33 |
| Azithromycin | Azithromycin | 123 | 87 |
| Levetiracetam | Levetiracetam | 121 | 14 |
| Bupropion Xl | Bupropion Hcl | 118 | 43 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 117 | 36 |
| Sertraline Hcl | Sertraline Hcl | 115 | 26 |
| Celecoxib | Celecoxib | 104 | 37 |
| Trazodone Hcl | Trazodone Hcl | 104 | 24 |
| Warfarin Sodium | Warfarin Sodium | 99 | 21 |
| Cephalexin | Cephalexin | 98 | 75 |
| Finasteride | Finasteride | 91 | 22 |
| Tramadol Hcl | Tramadol Hcl | 90 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 87 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 24 |
| Divalproex Sodium | Divalproex Sodium | 76 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 74 | 36 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 73 | 30 |
| Spironolactone | Spironolactone | 73 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 72 | 25 |
| Nifedipine Er | Nifedipine | 70 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 16 |
| Cefuroxime | Cefuroxime Axetil | 57 | 44 |
| Memantine Hcl Er | Memantine Hcl | 55 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 42 |
| Fenofibrate | Fenofibrate Nanocrystallized | 52 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 50 | suppressed |
| Ezetimibe | Ezetimibe | 46 | 13 |
| Midodrine Hcl | Midodrine Hcl | 46 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | suppressed |
| Methocarbamol | Methocarbamol | 44 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | 22 |
| Clonidine Hcl | Clonidine Hcl | 40 | 11 |
| Methenamine Hippurate | Methenamine Hippurate | 40 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 18 |
| Metronidazole | Metronidazole | 39 | 34 |
| Alendronate Sodium | Alendronate Sodium | 38 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 38 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 30 |
| Enulose | Lactulose | 37 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 36 | suppressed |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Baclofen | Baclofen | 34 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | 16 |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 20 |
| Xarelto | Rivaroxaban | 30 | 12 |
| Bumetanide | Bumetanide | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 28 | suppressed |
| Glimepiride | Glimepiride | 28 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 28 | suppressed |
| Latanoprost | Latanoprost | 28 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 27 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 27 | suppressed |
| Klor-Con M20 | Potassium Chloride | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 23 | 23 |
| Divalproex Sodium Er | Divalproex Sodium | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 16 |
| Lorazepam | Lorazepam | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Metolazone | Metolazone | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Nystatin | Nystatin | 17 | 13 |
| Tobramycin | Tobramycin | 17 | 12 |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Diazepam | Diazepam | 15 | 11 |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Fingolimod | Fingolimod Hcl | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $293.26 · 15 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ABRYSVO, CAPLYTA, COMIRNATY, ELIQUIS, INSPIRE, KISUNLA, NURTEC ODT, PAXLOVID, PREVNAR 20, QULIPTA, The Cologuard Plus Collection Kit, UBRELVY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error